Skip to content

An open label, crossover study to investigate the safety and tolerability of Sifrol® (pramipexole) (Boehringer Ingelheim) prolonged release tablets in order to establish the maximum tolerable dose and to assess bioequivalence of Pramipexole prolonged release tablets (Synthon B.V.) compared to Sifrol® prolonged release tablets (Boehringer Ingelheim) in healthy subjects in steady-state conditions

An open label, crossover study to investigate the safety and tolerability of Sifrol® (pramipexole) (Boehringer Ingelheim) prolonged release tablets in order to establish the maximum tolerable dose and to assess bioequivalence of Pramipexole prolonged release tablets (Synthon B.V.) compared to Sifrol® prolonged release tablets (Boehringer Ingelheim) in healthy subjects in steady-state conditions - CT.PAL.mrt.45.12.001

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON36833
Enrollment
52
Registered
2012-08-02
Start date
2012-08-15
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

parkinson's disease

Interventions

The study will start with a screening At the screening a physical examination will take place and a few other standard medical assessments will be performed ( Vital Signs). Furthermore a blood and u

Sponsors

Synthon B.V
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Healthy, non-smoking, non-vegetarian, Caucasian male volunteers, 18 - 55 years of age, inclusive.;2. Body Mass Index (BMI) that is within 18.5-30.0 kg/m², inclusive.;3. Healthy, according to the medical history, ECG, vital signs, laboratory results and physical examination as determined by Principal Investigator/Sub-Investigator.;4. Supine blood pressure between 90-150 mm Hg, inclusive, systolic and 50-90 mm Hg, inclusive, diastolic and heart rate between 50-100 bpm, inclusive, unless deemed otherwise by the Principal Investigator/Sub-Investigator. ;Refer to protocol for a complete list of the inclusion criteria.

Exclusion criteria

Exclusion criteria: 1. Known history or presence of any medical conditon determined as clinically significant by Principal Investigator/Sub-Investigator.;2. Out of range creatinine clearance in plasma according to Cockroft and Gault.;3. Known history or presence of drug or alcohol abuse, any relevant history of sleep disorder, food allergies ;Refer to protocol for a complete list of the inclusion criteria

Design outcomes

Primary

MeasureTime frame
safety, tolerability and bioequivalence

Secondary

MeasureTime frame
n.a.p

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)